Caron Ketone AUD withdrawal study
Brief description of study
To examine the effects of ketone supplement, Kenetik (KS) three times daily (TID), verse placebo, on the need for benzodiazepines and CIWA scores, while undergoing in-patient acute withdrawal management.To test the effects of Ketone Supplementation (KS) Kenetik in reducing alcohol withdrawal signs and symptoms and the need for medications to control them (benzodiazepines and comfort medications) in AUD inpatients during alcohol detoxification The primary outcome variable the daily amount of Benzodiazepine intake during the first 5 days of alcohol withdrawal management. We expect that subjects treated with KS will require less benzodiazepine medication than the placebo group. The secondary outcome variable is the total daily maximum CIWA-Ar score during the first week of alcohol withdrawal management. We expect that subjects treated with KS will have lower daily maximum CIWA-AR scores during the 5 days of alcohol withdrawal management.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
